ReviewCurrent gastroenterology reports2012
Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases?
Review in Current gastroenterology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Kefir: A protective dietary supplementation against viral infection.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Loss of CNFY toxin-induced inflammation drives Yersinia pseudotuberculosis into persistency.PLoS pathogens · 2018Article
- Colonization with Escherichia coli EC 25 protects neonatal rats from necrotizing enterocolitis.PloS one · 2017Article
- Vaccine against Helicobacter pylori: Inevitable approach.World journal of gastroenterology · 2016Review
- Genetic and Metabolic Signals during Acute Enteric Bacterial Infection Alter the Microbiota and Drive Progression to Chronic Inflammatory Disease.Cell host & microbe · 2016Article
- Impact of kefir derived Lactobacillus kefiri on the mucosal immune response and gut microbiota.Journal of immunology research · 2015Article
- Bugs or drugs: are probiotics safe for use in the critically ill?Current gastroenterology reports · 2014Review
- Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance.Current pharmaceutical design · 2014Review
- A current update on the rule of alternative and complementary medicine in the treatment of liver diseases.Evidence-based complementary and alternative medicine : eCAM · 2013Review
- Microbial regulation of allergic responses to food.Seminars in immunopathology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Probiotics, when considered in clinical practice, have traditionally been used for prophylaxis; however, there is growing data suggesting treatment benefits in numerous disease states. In this review, we focus on probiotics as treatment for and prevention of several acute and chronic infectious processes including Helicobacter pylori, Clostridium difficile, necrotizing enterocolitis, ventilator-associated pneumonia, vancomycin-resistant enterococci, and nonalcoholic fatty liver disease. It is inaccurate to generalize findings observed in a single probiotic species to all probiotics. This reasoning is due to the variability of colonizing abilities of native intestinal floras, probiotic or otherwise, secondary to different combinations, doses, and duration of treatments. Given these limitations, multiple animal and human studies have shown anti-inflammatory and selective antimicrobial effects of specific probiotics. Some studies suggest a role for probiotics as supplemental treatment, in combination with antibiotics, for the aforementioned disease processes. It is apparent from this review that the efficacy of probiotics is widely variable and multifaceted. More focused clinical and basic science research is necessary to better understand the treatment potential of various probiotics.
Indexed as
Identifiers
22763792What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.